A method for establishing a non-human
primate animal model of parkinson
disease by lateral
ventricle administration of MPP<+> belongs to the
biomedical technology. The method comprises the following steps: 1, preparing a lateral
ventricle administration device; 2, according to a monkey
brain atlas and
nuclear magnetic resonance imaging data, acquiring a positioning coordinate of a lateral
ventricle; 3, inserting a
catheter into a lateral ventricle administration position through a monkey stereotaxic instrument, and beginning to administrate the
drug after 5-8 days after the animal recovers; injecting a
physiological saline solution containing MPP<+> into the lateral ventricle by an
injector connected with the
tail end of an administration
pipe, with the MPP<+> concentration of 0.5-0.7 mg / mL and each administration dosage of 0.1-0.3 mL; carrying out administration one time every 48-72 hours, and after administration for 30-60 days, establishing the non-human
primate animal model of the parkinson
disease. The method employs a new administration mode that the MPP<+> (1-methyl-4-phenylpyridinium
iodide)
drug is directly injected into the lateral ventricle of the animal for modeling. With lateral ventricle injection, MPP<+> can perform whole brain circulation together with
cerebrospinal fluid to specifically damage
dopamine neurons in a brain and cause symptoms of the parkinson
disease, and can furthest avoid toxic and side effects of the
drug on a periphery.